Johnson & Johnson (NYSE:JNJ) shares bought by Wellington Shields & Co. IIC

VaselineSeptember 13, 2024

0 4 minutes read

Wellington Shields & Co. LLC raised its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,845 shares of the company’s stock after buying an additional 250 shares during the quarter. Johnson & Johnson makes up about 0.8% of Wellington Shields & Co.’s portfolio. LLC, making the stock its 25th largest holding. Wellington Shields & Co. holdings. LLC in Johnson & Johnson were worth $2,316,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Citizens & Northern Corp boosted its stake in Johnson & Johnson by 3.5% in the second quarter. Citizens & Northern Corp now owns 1,884 shares of the company’s stock valued at $275,000 after purchasing an additional 63 shares during the period. Carolinas Wealth Consulting LLC grew its holdings in Johnson & Johnson by 0.4% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock worth $2,643,000 after buying an additional 64 shares during the period. shares in the last quarter. Epic Trust Investment Advisors LLC grew its position in Johnson & Johnson by 3.6% during the 2nd quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock valued at $268,000 after buying an additional 64 shares during that period. Verity Asset Management Inc. boosted its stake in shares of Johnson & Johnson by 2.0% in the fourth quarter. Verity Asset Management Inc. now owns 3,268 shares of the company’s stock valued at $512,000 after buying an additional 65 shares during the last quarter. Finally, Outfitter Financial LLC raised its stake in Johnson & Johnson by 0.4% during the second quarter. Outfitter Financial LLC now owns 16,632 shares of the company’s stock worth $2,431,000 after purchasing an additional 65 shares in the last quarter. 69.55% of the shares are held by hedge funds and other institutional investors.

Johnson & Johnson trades down 0.1%

Shares of Johnson & Johnson stock opened at $164.64 on Friday. The company has a market cap of $396.24 billion, a price-to-earnings ratio of 10.26, a P/E/G ratio of 2.71 and a beta of 0.53. The firm has a 50-day moving average of $159.17 and a 200-day moving average of $154.00. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07, and a quick ratio of 0.85. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Want more great investment ideas?

Johnson & Johnson (NYSE:JNJ – Get Free Report ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s quarterly revenue was up 4.3% year over year. In the same quarter last year, the firm earned $2.80 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a $1.24 dividend. This represents a dividend of $4.96 on an annualized basis and a dividend yield of 3.01%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Analysts on Wall Street are forecasting an increase

A number of research firms recently weighed in on JNJ. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 30th. TD Cowen reduced their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd . StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 6th. Finally, Sanford C. Bernstein boosted their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Moderate Buy” and an average target price of $173.21, according to MarketBeat .

Check out our latest analysis of JNJ

Indoor activity

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The sale was disclosed in a filing with the SEC, which is available at this link. 0.16% of shares are held by insiders.

Johnson & Johnson profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.